Изменение эритроцитов и продуктов их деградации под действием SARS-CoV-2

Обложка

Цитировать

Полный текст

Аннотация

Представлены современные отечественные и зарубежные литературные данные о влиянии SARS-CoV-2 на эритроциты при COVID-19 и о влиянии образовавшихся продуктов деградации эритроцитов на организм. Подробно анализируются механизмы детоксикации этих продуктов и возможность рассматривать их в качестве биомаркеров этого тяжелейшего заболевания, а также терапевтических мишеней для борьбы с ним.

Полный текст

Доступ закрыт

Об авторах

М. Г. Голубева

Московский государственный университет им. М.В. Ломоносова

Автор, ответственный за переписку.
Email: Mgolubeva46@mail.ru

биологический факультет

Россия, Москва

Список литературы

  1. Беляков Н.А., Рассохин В.В., Ястребова Е.Б. Лекция: Коронавирусная инфекция COVID-19. Ч. 1. Природа вируса, патогенез, клинические проявления. СПб.: ПСПбГМУ им. И.П. Павлова, 2020. С. 1–18.
  2. Гайнуллина Д.К., Кирюхина О.О., Тарасова О.С. Оксид азота в эндотелии сосудов: регуляция продукции и механизмы действия // Успехи физиол. наук. 2013. № 4. С. 88–102.
  3. Голубева М.Г. Осмотическая резистентность эритроцитов, методы определения и коррекции, значение при различных патологиях // Успехи соврем. биол. 2019. Т. 139 (5). С. 446–456.
  4. Голубева М.Г. Роль Р-селектина в развитии нарушений гемостаза при COVID-19 // Успехи соврем. биол. 2022. Т. 142 (2). С. 175–183.
  5. Голубева М.Г. Роль гаптоглобина в защите организма от токсического действия внеклеточного гемоглобина // Успехи соврем. биол. 2023. Т. 143 (2). С. 114–122.
  6. Смирнов В.С., Тотолян А.А. Врожденный иммунитет при коронавирусной инфекции // Инфек. иммун. 2020. Т. 10 (2). С. 259–268.
  7. Abbas Y.M., Toye A.M., Rubinstein J.L., Reithmeier R.A.F. Band 3 function and dysfunction in a structural context // Curr. Opin. Hematol. 2018. V. 25 (3). P. 163–170.
  8. Abdelhafez M. Protective and therapeutic potentials of HDL and ApoA1 in COVID-19 elderly and chronic illness patients // Bull. Natl. Res. Cent. 2022. V. 46. P. 222.
  9. Abrahams L. COVID-19: acquired acute porphyria hypothesis. 2020. https://doi.org/10.31219/osf.io/4wkfycc
  10. Adamzik M., Hamburger Т., Petrat F. et al. Free hemoglobin concentration in severe sepsis: methods of measurement and prediction of outcome // Crit. Care. 2012. V. 16 (4). P. R125.
  11. Akhter N., Ahmad S., Alzahrani F.A. et al. Impact of COVID-19 on the cerebrovascular system and the prevention of RBC lysis // Eur. Rev. Med. Pharmacol. Sci. 2020. V. 24 (19). P. 10267–10278.
  12. Algassim A.A., Elghazaly A.A., Alnahdi A.S. et al. Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection // Ann. Hematol. 2021. V. 100. P. 37–43.
  13. Alipoor S., Mirsaeidi M. SARS-CoV-2 cell entry beyond the ACE2 receptor // Mol. Biol. Rep. 2022. V. 49 (11). P. 10715–10727.
  14. Alipoor S.D., Mortaz E., Jamaati H. et al. COVID-19: molecular and cellular response // Front. Cell. Infect. Microbiol. 2021a. V. 11. P. 563085.
  15. Alipoor S.D., Mortaz E., Varahram M. et al. The immunopathogenesis of neuroinvasive lesions of SARS-CoV-2 infection in COVID-19 patients // Front. Neurol. 2021b. V. 12. P. 697079.
  16. Al-Kuraishy H.M., Al-Gareeb A., Kaushik A. et al. Hemolytic anemia in COVID-19 // Ann. Hematol. 2022. V. 101 (9). P. 1887–1895.
  17. Aoki T. A comprehensive review of our current understanding of red blood cell (RBC) glycoproteins // Membranes. 2017. V. 7 (4). P. 56.
  18. Ascenzi P., Bocedi A., Visca P. et al. Hemoglobin and heme scavenging // IUBMB Life. 2005. V. 57 (11). Р. 749–759.
  19. Ashouri R., Fangman M., Burris A. et al. Critical role hemopexin mediated cytoprotection in the pathophysiology of sickle cell disease // Int. J. Mol. Sci. 2021. V. 22 (12). P. 6408.
  20. Aydemir D., Dağlıoğlu G., Candevir A. et al. COVID-19 may enhance risk of thrombosis and hemolysis in the G6PD deficient patients // Nucl. Nucleot. Nucl. Acids. 2021. V. 40. P. 505–517.
  21. Böning D., Kuebler W., Bloch W. The oxygen dissociation curve of blood in COVID-19 // Am. J. Physiol. Lung Cell. Mol. Physiol. 2021. V. 321. P. L349–L357.
  22. Brzeszcznska J., Gwozdzinski K. Nitric oxide induced oxidative changes in erythrocyte membrane components // Cell Biol. Int. 2008. V. 32 (1). P. 114−120.
  23. Cameron K., Rozano L., Falasca M., Mancera R.L. Does the SARS-CoV-2 spike protein receptor binding domain interact effectively with the DPP4 (CD26) receptor? A molecular docking study // Int. J. Mol. Sci. 2021. V. 22 (13). P. 7001.
  24. Cantuti-Castelvetri L., Ojha R., Pedro L. et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity // Science. 2020. V. 370 (6518). P. 856–860.
  25. Carbajo-Lozoya J., Ma-Lauer Y., Malešević M. et al. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir // Virus Res. 2014. V. 184. P. 44–53.
  26. Сhen K., Popel A.S. Nitric oxide production pathways in erythrocytes and plasma // Biorheology. 2009. V. 46 (2). P. 107−119.
  27. Chen L., Mehta J. Evidence for the presence of L-arginine–nitric oxide pathway in human red blood cells: relevance in the effect of red blood cells on platelet function // J. Cardiovasc. Pharmacol. 1998. V. 32 (1). P. 57−61.
  28. Chen Z., Mi L., Xu J. et al. Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus // J. Infect. Dis. 2005. V. 191. P. 755–760.
  29. Cosic I., Cosic D., Loncarevic I. RRM prediction of erythrocyte Band3 protein as alternative receptor for SARS-CoV-2 virus // Appl. Sci. 2020. V. 10 (11). P. 4053.
  30. Daly J.L., Simonetti B., Klein K. et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection // Science. 2020. V. 370 (6518). P. 861–865.
  31. Deuel J., Schaer C., Boretti F.S. et al. Hemoglobinuria-related acute kidney injury is driven by intrarenal oxidative reactions triggering heme toxicity response // Cell Death Dis. 2016. V. 7 (1). P. e2064.
  32. Effenberger-Neidnicht K., Hartmann M. Mechanisms of hemolysis during sepsis // Inflammation. 2018. V. 41 (5). P. 1569–1581.
  33. Etzerodt A., Moestrup S.K. CD163 and inflammation: biological, diagnostic and therapeutic aspects // Antioxid. Redox Signal. 2013. V. 18 (17). P. 2352– 2363.
  34. Faghihi H. CD147 as an alternative binding site for the spike protein on the surface of SARS-CoV-2 // Eur. Rev. Med. Pharmacol. Sci. 2020. V. 24. P. 11992–11994.
  35. Foy B.H., Carlson J.C.T., Reinertsen E. et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection // JAMA Netw. Open. 2020. V. 3. P. e2022058.
  36. Griffiths S., Clark J., Adamides A.A., Ziogas J. The role of haptoglobin and hemopexin in the prevention of delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage: a review of current literature // Neurosurg. Rev. 2020. V. 43 (5). P. 1273–1288.
  37. Guo H.-F., Kooi C.W.V. Neuropilin function as an essential cell surface receptor // J. Biol. Chem. 2015. V. 290 (49). P. 29120–29126.
  38. Hamburger T., Broecker-Preuss M., Hartmann M. et al. Effects of glycine, pyruvate, resveratrol, and nitrite on tissue injury and cytokine response in endotoxemic rats // J. Surg. Res. 2013. V. 183. P. e7–e21.
  39. Hartmann M., De Groot H. Cell-free hemoglobin: a new player in sepsis pathophysiology // Crit. Care Med. 2013. V. 41 (8). P. e186–e189.
  40. Helal M.A., Shouman S., Abdelwaly A. et al. Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia // J. Biomol. Struct. Dyn. 2020. V. 16. P. 1109–1119.
  41. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor // Cell. 2020. V. 181 (2). P. 271–280.
  42. Hvidberg V., Manieki M.B., Jacobsen C. et al. Identification of the receptor scavenging hemopexin–heme complexes // Blood. 2005. V. 106 (7). P. 2572–2579.
  43. Janz D.R., Ware L.B. The role of red blood cells and cell-free hemoglobin in the pathogenesis of ARDS // J. Intensive Care. 2015. V. 3. P. 20.
  44. Janz D.R., Bastarache J.A., Peterson J.F. et al. Association between cell-free hemoglobin, acetaminophen, and mortality in patients with sepsis: an observational study // Crit. Care Med. 2013. V. 41. P. 784–790.
  45. Jobe A., Vijayan R. Neuropilins: C-end rule peptides and their association with nociception and COVID-19 // Comput. Struct. Biotechnol. J. 2021. V. 19. P. 1889–1895.
  46. Kai H., Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors – lessons from available evidence and insights into COVID-19 // Hypertens. Res. 2020. V. 43 (7). P. 648–654.
  47. Kichloo A., Dettloff K., Aljadah M. et al. COVID-19 and hypercoagulability: a review // Clin. Appl. Thromb. Hemost. 2020. V. 26. P. 1076029620962853.
  48. Kirtipal N., Kumar S., Dubey S.K. et al. Understanding on the possible routes for SARS-CoV-2 invasion via ACE2 in the host linked with multiple organs damage // Infect. Genet. Evol. 2022. V. 99. P. 105254.
  49. Kowal K., Silver R., Sławińska E. et al. CD163 and its role in inflammation // Folia Histochem. Cytobiol. 2011. V. 49 (3). P. 365–374.
  50. Kumar S., Thambiraja T.S., Karuppanan K., Subramaniam G. Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein // J. Med. Virol. 2022. V. 94. P. 1641–1649.
  51. Lansink M.O., Görlinger K., Hartmann M. et al. Melatonin does not affect disseminated intravascular coagulation but diminishes decreases in platelet count during subacute endotoxaemia in rats // Thromb. Res. 2016. V. 139. P. 38–43.
  52. Larsen R., Gozzelino R., Jeney V. et al. A central role for free heme in the pathogenesis of severe sepsis // Sci. Transl. Med. 2010. V. 2. P. 51ra71.
  53. Lecerf M., Scheel T., Pashov A.D. et al. Prevalence and gene characteristics of antibodies with cofactor-induced HIV-1 specificity // J. Biol. Chem. 2015. V. 290. P. 5203–5213.
  54. Li W., Moore M.J., Vasilieva N. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus // Nature. 2003. V. 426 (6965). P. 450–454.
  55. Lippi G., Mattiuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019 // Hematol. Transfus. Cell Ther. 2020. V. 42. P. 116–117.
  56. Loh D. The potential of melatonin in the prevention and attenuation of oxidative hemolysis and myocardial injury from CD147 SARS-CoV-2 spike protein receptor binding // Melatonin Res. 2020. V. 3 (3). P. 380–416.
  57. Lu R., Zhao X., Li J. et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding // Lancet. 2020. V. 395. P. 565–574.
  58. Luo C., Luo H., Zheng S. et al. Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A // Biochem. Biophys. Res. Commun. 2004. V. 321. P. 557–565.
  59. Mayi B.S., Leibowitz J.A., Woods A.T. et al. The role of neuropilin-1 in COVID-19 // PLoS Pathog. 2021. V. 17. P. e1009153.
  60. Mendonça M., Cruss K., Pinheiro D. et al. Dysregulation in erythrocyte dynamics caused SARS-CoV-2 infection: possible role in shuffling the homeostatic puzzle during COVID-19 // Hematol. Transfus. Cell Ther. 2022. V. 44 (2). P. 235–245.
  61. Mlcochova P., Kemp S.A., Dhar M.S. et al. SARS-CoV-2 B.1.617.2 Delta variants replication and immune evasion // Nature. 2021. V. 599. P. 114–119.
  62. Moreno-Torres V., Sánchez-Chica E., Castejón R. et al. Red blood cell distribution width as a marker of hyperinflammation and mortality in COVID-19 // Ann. Palliat. Med. 2022. V. 11. P. 2609–2621.
  63. Nieto-Torres J.L., Verdiá-Báguena C., Jimenez-Guardeño J.M. et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome // Virology. 2015. V. 485. P. 330–339.
  64. Nishibori M. Novel aspects of sepsis pathophysiology: NETs, plasma glycoproteins, endotheliopathy and COVID-19 // J. Pharmacol. Sci. 2022. V. 150 (1). P. 9–20.
  65. Osti N., Ceolan J., Piccoli P. et al. Acute hemolysis by cold antibody during SARS-CoV-2 infection in a patient with Evans syndrome: a case report and literature review // Blood Transfus. 2022. V. 20 (2). P. 168–172.
  66. Ousaka D., Nishibori M. A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs // Nihon Yakurigaku zasshi. 2022a. V. 157 (6). P. 422–425.
  67. Ousaka D., Nashibori M. Is hemolysis a novel therapeutic target in COVID-19? // Front. Immunol. 2022b. V. 13. P. 956671.
  68. Papandopoulos C., Spourita E., Tentes I. et al. Red blood cell malfunction in COVID-19 molecular mechanisms and therapeutic targets // Viral Immunol. 2022. V. 35 (10). P. 649–652.
  69. Pennings G.J., Kritharides L. CD147 in cardiovascular disease and thrombosis // Semin. Thromb. Hemost. 2014. V. 40. P. 747–755.
  70. Pia L., Rowland-Jones S. Omicron entry route // Nat. Rev. Immunol. 2022. V. 22 (3). P. 144.
  71. Pita Zapata E., Sarmiento Penide A., Bautista Guillén B. Massive intravascular hemolysis secondary to sepsis due to Clostridium perfingens // Rev. Esp. Anesthesiol. Reanim. 2010. V. 57 (3). P. 314–316.
  72. Pushkarsky T., Zybarth D., Dubrovsky L. et al. CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A // PNAS USA. 2001. V. 98 (11). P. 6360–6365.
  73. Rapozzi V., Juarranz A., Habib A. et al. Is haem the real target of COVID–19? // Photodiagn. Photodyn. Ther. 2021. V. 35. P. 102381.
  74. Redaelli S., Magliocca A., Malhotra R. et al. Nitric oxide: clinical applications in critically ill patients // Nitric Oxide. 2022. V. 121. P. 20–33.
  75. Reiter C.D., Wang X., Tanus-Santos J.E. et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease // Nat. Med. 2002. V. 8 (12). P. 1383–1389.
  76. Roy S., Bag A.K., Singh R.K. et al. Multifaceted role of neurothelin’s in the immune system: potential targets for immunotherapy // Front. Immunol. 2017. V. 8. P. 1228.
  77. Sahu K.K., Borogovac A., Cerny J. COVID‐19 related immune hemolysis and thrombocytopenia // J. Med. Virol. 2021. V. 93 (2). P. 1164–1176.
  78. Saphire A., Bobardt M.D., Gallay P.A. Human immunodeficiency virus type 1 hijacks host cyclophilin A for its attachment to target cells // Immunol. Res. 2000. V. 21. P. 211–217.
  79. Schaer C.A., Deuel J.W., Bittermann A.G. et al. Mechanisms of haptoglobin protection against hemoglobin peroxidation triggered endothelial damage // Cell Death Differ. 2013. V. 20 (11). P. 1569–1579.
  80. Scialo F., Daniele A., Amato F. et al. ACE2: the major cell entry receptor for SARS-CoV-2 // Lung. 2020. V. 198. P. 867–877.
  81. Shver C.M., Upchurch C.P., Janz D.R. et al. Cell-free hemoglobin: a novel mediator of acute lung injury // Am. J. Physiol. Lung Cell. Mol. Physiol. 2016. V. 310. P. L532–L541.
  82. Su W.-L., Lin C.-P., Hang H.-C. et al. Desaturation and heme elevation during COVID-19 infection: a potential prognostic factor of heme oxygenase-1 // J. Microbiol. Immunol. Infect. 2021. V. 54. P. 113–116.
  83. Tai W., He L., Zhang X. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine // Cell. Mol. Immunol. 2020. V. 17. P. 613–620.
  84. Thomas T., Stefanoni D., Dzieciatkowska M. et al. Evidence of structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients // J. Proteome Res. 2020. V. 19. P. 4455–4469.
  85. Vallelian F., Buehler P., Schaer D. Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics // Blood. 2022. V. 140 (17). P. 1837–1844.
  86. van Avondt K., Nur E., Zeerleder S. Mechanisms of haemolysis-induced kidney injury // Nat. Rev. Nephrol. 2019. V. 15 (11). P. 671–692.
  87. Vankadari N., Wilce J.A. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 // Emerg. Microbes Infect. 2020. V. 9 (1). P. 601–604.
  88. Verdecchia P., Cavallini C., Spanevello A., Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection // Eur. J. Intern. Med. 2020. V. 76. P. 14–20.
  89. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China // JAMA. 2020. V. 323. P. 1061–1069.
  90. Wang H.-B., Zhang H., Zhang J.-P. et al. Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells // Nat. Commun. 2015. V. 6. P. 6240.
  91. Wang K., Chen W., Zhang Z. et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells // Signal Transduct. Target. Ther. 2020a. V. 5 (1). P. 283.
  92. Wang K., Chen W., Zhou Y.-S. et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein // bioRxiv. 2020b. https://doi.org/10.1101/2020.03.14.988345
  93. Wang Q., Qi J., Yuan Y. et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26 // Cell Host Microbe. 2014. V. 16 (3). P. 328–337.
  94. Wang R., Shen Q., Li X. et al. Efficacy of inversо isomer of CendR peptide on tumor tissue penetration // Acta Pharm. Sin. B. 2018. V. 8 (5). P. 825–832.
  95. WHO. 2021. Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novelcoronavirus-2019
  96. Wu F., Zhao S., Yu B. et al. A new coronavirus associated with human respiratory disease in China // Nature. 2020. V. 579. P. 265–269.
  97. Yurchenko V., Constant S., Eisenmesser E., Bukrinsky M. Cyclophilin–CD147 interactions: a new target for anti-inflammatory therapeutics // Clin. Exp. Immunol. 2010. V. 160 (3). P. 305–317.
  98. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. 2020. V. 395. P. 1054–1062.
  99. Zou X., Chen K., Zou J. et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection // Front. Med. 2020. V. 14 (2). P. 185–192.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Российская академия наук, 2024